Sanofi (NASDAQ:SNY) Q3 2023 Earnings Conference Call October 27, 2023 9:00 AM ET
Company Participants
Eva Schaefer-Jansen - Head of Investor Relations
Paul Hudson - Chief Executive Officer
Jean-Baptiste de Chatillon - Executive Vice President, Chief Financial Officer
Houman Ashrafian - Global Head of R&D
Julie Van Ongevalle - Executive Vice President, Consumer Healthcare
Brian Ford - Head Specialty Care, North America and US Country Lead
Thomas Triomphe - Executive Vice President, Vaccines
Olivier Charmeil - Executive Vice President, General Medicines
Conference Call Participants
Luisa Hector - Berenberg
Emily Field - Barclays
Peter Welford - Jefferies
Graham Parry - BofA
Timothy Anderson - Wolfe
Peter Verdult - Citi
David Risinger - Leerink
Florent Cespedes - Societe Generale
Simon Baker - Redburn
Seamus Fernandez - Guggenheim
Richard Vosser - JPMorgan
Eva Schaefer-Jansen
[starts abruptly] You have joined the meeting as an attendee and will be muted throughout the meeting. This meeting is being recorded. 2023 results followed by a Q&A session. As usual, you can find the slides to this call on the investors page of our website at sanofi.com.
Moving to slide 3, I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document d’Enregistrement Universel for a description of these risk factors.
With this, please advance to slide 4. Our speakers on the call today are Paul Hudson, Chief Executive Officer, Jean-Baptiste de Chatillon, Chief Financial Officer, Houman Ashrafian, Global Head of R&D, and Julie Van Angeval, Global Business Unit Head, Consumer Health Care. The Global Business Unit Heads Brian Ford, Thomas Triomphe, and Olivier Charmeil will join for Q&A to which you have two options to participate. [Operator instructions].
And with that, I'd like to turn the call over to Paul.
Paul Hudson
Well, thank you, Eva, and thanks to everyone for joining our call today. Before we discuss this quarter's highlights, I want to start by updating you on other announcements we made this morning. We've reached an exciting moment in the transformation of our Company here at Sanofi.
Our play to win strategy is working and we've made significant progress over the past years to transform our R&D efforts with a sharp focus on best in class or first in class medicines and vaccines. These efforts are reflected in our results. We're driving solid performance, seeing strong market demand for our recent launches, and advancing our innovative pipeline.